Glass microspheres reduced to 1.5 microns; AMA wants FDA to treat e-cigarettes as a drug delivery device;

> Whitehouse Scientific says that it has been able to shrink the size of its glass microspheres from 10 microns to 1.5 microns. The tiny spheres can be used for drug delivery. Report

> Israel's Chiasma says that it has successfully completed an early-stage trial of an orally delivered peptide for acromegaly, a hormonal disorder that results from an excess of growth hormone. Octreolin demonstrated a PK profile similar to subcutaneously injected octreotide acetate. No serious adverse safety events were reported. Chiasma release

> Global Health Ventures says that it has begun work on Nico-Z, a sublingual formulation of nicotine that is incorporated through its technology to deliver the product rapidly to the blood stream. Announcement

> Stirling Products plans to have its Inhalation Drug Delivery Platform device available for testing by the first quarter of 2011. Report

And Finally... E-cigarettes, smokeless devices used to deliver nicotine to the user, are drug delivery devices that should be subject to FDA regulations, according to the American Medical Association. AMA release

Suggested Articles

Genentech's Port Delivery System with ranibizumab matched Lucentis eye injections in a late-stage, wet age-related macular degeneration trial.

Honeywell aims to wean the industry of its glass habit with Aclar Edge, a new line of bottles and vials made with the company's patented plastic.

Astex's oral reformulation of a common chemo combo looks to replace lengthy infusions with a once-daily tablet that patients can take at home.